Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | BMC Urology

Figure 1

From: miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer

Figure 1

(A) Graphical representation of the expression levels of miR-21 and RECK in 27 patients with PCa compared with BPH which included in two profiles: miR-21 overexpressed - RECK underexpressed, and miR-21 underexpressed - RECK overexpressed. (B) Graphical representation of the expression levels of miR-21 in PCa cell treated with pre-miR-21 e anti-miR-21. (C) Graphical representation of the expression levels of RECK and MMP9 in PCa cell treated with pre-miR-21 e anti-miR-21. Fold change in expression was calculated using the 2-ΔΔCT method.

Back to article page